Daily Ards Research Analysis

INTRODUCTION: Recent studies have demonstrated a beneficial role of steroids in severe community-acquired pneumonia, severe COVID-19 infection and acute respiratory distress syndrome (ARDS) of diverse aetiology. This multicentre randomised controlled trial in severe scrub typhus pneumonitis and ARDS will compare the effects of 6 mg of dexamethasone once per day with placebo, in addition to standard treatment, on ventilator-free days (VFD), mortality and ventilatory requirement. METHODS AND ANALYSIS: The study, involving six sites, will recruit 440 patients with severe scrub typhus pneumonitis or ARDS to concealed, block-randomised, site-specific assignment of dexamethasone or placebo for 4-7 days. The primary outcome will be VFD, defined as days alive and free of ventilation at 28 days. Secondary outcomes will include 28-day mortality, need and duration of ventilation, and treatment failure, defined as death, or escalation of respiratory support from simple devices (nasal cannula, mask) to non-invasive or invasive ventilation, or the use of open-labelled steroids for worsening shock. The study will also ascertain if antinuclear antibody (ANA) expression during the acute phase of illness will predict steroid responsiveness. Subgroup analyses will be conducted a priori on ANA expression and the need for ventilation. All analyses will be conducted on an intention-to-treat basis. The trial, which commenced in April 2025, would clarify the role of corticosteroids in scrub typhus pneumonitis. ETHICS AND DISSEMINATION: The Institutional Review Board and Ethics Committee of the lead site, Christian Medical College, Vellore, India, has approved the study (IRB Min No 15920 (INTERVE) dated 22 November 2023). The remaining five sites have obtained approval from their respective ethics committees. Study results will be published in an international peer-reviewed journal. TRIAL REGISTRATION NUMBER: CTRI/2024/12/077709. Registered 5 December 2024.

BACKGROUND: Acute respiratory distress syndrome (ARDS) is a critical and potentially fatal condition marked by inflammation and coagulation disorders. Statins, a class of cholesterol-lowering medications, have been explored for potential anti-inflammatory properties, yet their exact role in ARDS remains unclear. METHODS: Patients diagnosed with ARDS were sourced from the MIMIC-IV database (version 3.0). To balance baseline characteristics, propensity score matching (PSM) was applied. Short-term mortality was evaluated using Kaplan-Meier survival analysis. Factors associated with short-term mortality were determined using both univariate and multivariate Cox regression analyses. The potential impact of unmeasured confounding was assessed using the E-value. Additionally, subgroup analyses were performed to investigate heterogeneity and evaluate the robustness of the findings. RESULTS: The study included 10,368 ARDS patients, of whom 5,184 received statin therapy and 5,184 did not. Kaplan-Meier analysis revealed significantly lower short-term mortality in the statin-treated group. Both univariate (HR, 0.48; 95% CI, 0.41-0.58; CONCLUSION: Statin therapy appears to confer significant clinical benefits in ARDS patients, particularly in those with high non-HDL-C levels. These findings indicate that non-HDL-C might be a useful marker for identifying ARDS patients who may benefit most from statin therapy.

Increased epithelial and endothelial permeability, along with dysregulated inflammatory responses, are key aspects of acute respiratory distress syndrome (ARDS) pathophysiology, which not only impact the lungs but also contribute to detrimental organ crosstalk with distant organs, ultimately leading to multiple organ dysfunction syndrome (MODS)-the primary cause of morbidity and mortality in patients with lung injury (LI) and ARDS. It is predominantly manifested by hypoxemic respiratory failure and bilateral pulmonary infiltrates, which cannot be fully attributed to cardiac failure or hypervolemia, but rather to alveolo-capillary barrier dysfunction, dysregulated systemic and pulmonary inflammation, immune system abnormalities, and mechanical stimuli-related responses. However, these pathological features are not uniform among patients with ARDS, as distinct subphenotypes with unique biological, clinical, physiological, and radiographic characteristics have been increasingly recognized in recent decades. The severity of ARDS, clinical outcomes, mortality, and efficacy of applied therapeutic measures appear significant depending on the respective phenotype. Acknowledging the heterogeneity of ARDS and defining distinct subphenotypes could significantly modify therapeutic strategies, enabling more precise and targeted treatments. To address these issues, a comprehensive literature search was conducted in PubMed using predefined keywords related to ARDS pathophysiology, subphenotypes, and personalized therapeutic approaches. Optimizing the identification and characterization of discrete ARDS subphenotypes-based on clinical, biological, physiological, and radiographic criteria-will deepen our understanding of ARDS pathophysiology, promote targeted recruitment in prospective clinical studies to define patient clusters with heterogeneous therapeutic responses, and support the shift toward individualized treatment strategies.